• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study.

作者信息

Dhakal Binod, Zhang Mei-Jei, Burns Linda J, Tang Xiaoying, Meyer Christa, Mau Lih-Wen, Nooka Ajay K, Stadtmauer Edward, Micallef Ivana N, McGuirk Joseph, Costa Luciano, Juckett Mark B, Shah Nina, Champlin Richard E, Usmani Saad Z, Farag Sherif S, Nishihori Taiga, Roy Vivek, Bodiford Andrew, Barnes Yvonne J, Drea Edward J, Hari Parameswaran, Hamadani Mehdi

机构信息

BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee.

Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee.

出版信息

Haematologica. 2023 Aug 1;108(8):2249-2254. doi: 10.3324/haematol.2022.282269.

DOI:10.3324/haematol.2022.282269
PMID:36601982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10388259/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/587a/10388259/fc46e8d750ad/1082249.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/587a/10388259/fc46e8d750ad/1082249.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/587a/10388259/fc46e8d750ad/1082249.fig1.jpg

相似文献

1
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study.多发性骨髓瘤动员策略的疗效、安全性及成本：一项前瞻性观察性研究
Haematologica. 2023 Aug 1;108(8):2249-2254. doi: 10.3324/haematol.2022.282269.
2
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.培洛昔福联合粒细胞集落刺激因子在淋巴瘤和多发性骨髓瘤一线稳定期自体外周血造血干细胞动员中的应用：前瞻性 PREDICT 试验结果。
Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.
3
Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.干细胞释放化合物普乐沙福用于骨髓瘤患者外周血干细胞采集的长期安全性。
Hematol Oncol. 2023 Aug;41(3):583-586. doi: 10.1002/hon.3055. Epub 2022 Aug 6.
4
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.在恶性淋巴瘤或多发性骨髓瘤患者中，在使用粒细胞集落刺激因子的基础上加用普乐沙福用于造血干细胞动员以进行自体移植。
Cochrane Database Syst Rev. 2015 Oct 20;2015(10):CD010615. doi: 10.1002/14651858.CD010615.pub2.
5
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.一项关于新型药物治疗多发性骨髓瘤患者用环磷酰胺联合粒细胞集落刺激因子和按需使用plerixafor进行造血干细胞动员的前瞻性、多中心研究。
Haematologica. 2024 May 1;109(5):1525-1534. doi: 10.3324/haematol.2023.284023.
6
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞：一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.
7
Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review.培瑞克昔福在动员和白细胞去除自体移植造血干细胞中的经济评价：系统评价。
Expert Rev Pharmacoecon Outcomes Res. 2023 Jan;23(1):15-28. doi: 10.1080/14737167.2023.2140140. Epub 2022 Nov 24.
8
Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.plerixafor 用于自体造血细胞移植动员的策略：疗效和成本比较。
Transfus Apher Sci. 2022 Apr;61(2):103303. doi: 10.1016/j.transci.2021.103303. Epub 2021 Oct 30.
9
On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone.对于单独使用粒细胞集落刺激因子（G-CSF）存在动员失败风险的轻链淀粉样变性患者，按需使用普乐沙福进行造血祖细胞动员是安全有效的。
Bone Marrow Transplant. 2023 May;58(5):610-612. doi: 10.1038/s41409-023-01938-0. Epub 2023 Feb 24.
10
Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.使用普乐沙福在镰状细胞病患者中进行安全有效的外周血干细胞采集。
Haematologica. 2020 Oct 1;105(10):e497. doi: 10.3324/haematol.2019.236182.

引用本文的文献

1
Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab.在接受或不接受达雷妥尤单抗诱导治疗的新诊断多发性骨髓瘤患者中，于自体干细胞移植前使用粒细胞集落刺激因子（G-CSF）联合或不联合环磷酰胺动员造血干细胞。
Bone Marrow Transplant. 2025 Aug 30. doi: 10.1038/s41409-025-02681-4.
2
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.造血干细胞动员效果不佳的多发性骨髓瘤患者接受第二次自体造血细胞移植后的满意结局：一项代表欧洲血液与骨髓移植协会慢性恶性肿瘤工作组开展的回顾性研究
Bone Marrow Transplant. 2025 Feb;60(2):211-219. doi: 10.1038/s41409-024-02460-7. Epub 2024 Nov 12.
3

本文引用的文献

1
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.卡非佐米联合环磷酰胺和地塞米松或来那度胺和地塞米松联合自体移植，或卡非佐米联合来那度胺和地塞米松，随后用卡非佐米联合来那度胺或来那度胺维持治疗新诊断的多发性骨髓瘤患者（FORTE）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
2
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.来那度胺、硼替佐米与地塞米松联合移植治疗骨髓瘤
N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.
3
Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.在多发性骨髓瘤患者的自体干细胞移植中使用和不使用普乐沙福的动员策略。
Bone Marrow Transplant. 2024 Oct;59(10):1440-1448. doi: 10.1038/s41409-024-02385-1. Epub 2024 Jul 31.
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.异环磷酰胺、卡铂和依托泊苷化疗与普乐沙福为基础的策略用于霍奇金淋巴瘤和非霍奇金淋巴瘤患者造血祖细胞动员的比较
Biol Blood Marrow Transplant. 2016 Oct;22(10):1773-1780. doi: 10.1016/j.bbmt.2016.06.016. Epub 2016 Jun 21.
4
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.在多发性骨髓瘤中，用于干细胞动员的初治普乐沙福加粒细胞集落刺激因子与环磷酰胺加粒细胞集落刺激因子的疗效和成本分析研究。
Bone Marrow Transplant. 2016 Apr;51(4):546-52. doi: 10.1038/bmt.2015.322. Epub 2016 Jan 4.
5
Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.采用“即时”普乐沙福方案进行造血祖细胞动员是常规使用普乐沙福的一种经济有效的替代方法。
Cytotherapy. 2015 Dec;17(12):1785-92. doi: 10.1016/j.jcyt.2015.09.002. Epub 2015 Oct 21.
6
G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.粒细胞集落刺激因子（G-CSF）联合抢先使用普乐沙福与超分割环磷酰胺（CY）联合G-CSF用于多发性骨髓瘤自体干细胞动员：有效性、安全性及成本分析
Bone Marrow Transplant. 2015 Jun;50(6):813-7. doi: 10.1038/bmt.2015.23. Epub 2015 Mar 9.
7
Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.与培洛昔康和 G-CSF 相比，新型疗法治疗多发性骨髓瘤患者中，中剂量环磷酰胺和 G-CSF 动员 PBSC 的疗效相当，但成本更低。
Bone Marrow Transplant. 2013 Oct;48(10):1279-84. doi: 10.1038/bmt.2013.52. Epub 2013 Apr 15.
8
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.尽管先前使用过来那度胺，但生长因子加预防性（“及时”）plerixafor 成功动员多发性骨髓瘤患者的造血干细胞。
Bone Marrow Transplant. 2012 Nov;47(11):1403-8. doi: 10.1038/bmt.2012.60. Epub 2012 Apr 9.
9
Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy.依托泊苷化学动员在多发性骨髓瘤患者中非常有效，并克服了年龄和既往治疗的影响。
Biol Blood Marrow Transplant. 2011 Jan;17(1):141-6. doi: 10.1016/j.bbmt.2010.06.021. Epub 2010 Jul 15.
10
Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.培洛利昔（plerixafor）联合生长因子与环磷酰胺和生长因子相比，更有利于自体造血干细胞的动员。
Bone Marrow Transplant. 2011 Apr;46(4):523-8. doi: 10.1038/bmt.2010.170. Epub 2010 Jul 12.